other studies indicated that lateral temporal lobe [12] or temporal pole hypometabolism [13] were better predictors of a seizure-free postoperative outcome. Most of the prior studies included ...

"These early results from the first trial participant are very encouraging and support our belief that AMT-260 has the potential to be a valuable treatment alternative for people living with ...

Inspiration for this work has come from a group of patients who have a brain disorder called temporal lobe epilepsy. In a minority of patients, this condition induces bizarre religious hallucinations ...

Epilepsy is a chronic neurological disorder characterised by recurrent seizures. While seizures are the most recognisable ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conf ...

Surgeons from the University of Arkansas for Medical Sciences (UAMS) have performed the first transplantation in Arkansas of ...

Childhood memories have a way of lingering—sometimes filling us with nostalgia for simpler days when imagination knew no ...

UAMS recently became the first in the state to transplant interneuron cell therapy into the brain of a patient with ...